MHRA successfully reclassifies Dovonex Psoriasis Ointment
Medicines and Healthcare products Regulatory Agency (MHRA) have today announced the approval of Dovonex Psoriasis 50microgram/g Ointment, which will be available through pharmacies without prescription.
Following a successful public consultation, Dovonex Psoriasis Ointment will be available through pharmacies without a prescription.
The Commission on Human Medicines (CHM) advised in favour of the product being available in pharmacies for the treatment of mild to moderate plaque psoriasis which has been previously diagnosed by a doctor in adults aged 18 years and over. The treatment is for application once daily, with maximum duration of use of 12 weeks and maximum pack size of 60g of ointment.
Pharmacists are trained healthcare professionals and will have access to training materials to enable them to identify patients that can be supplied this medicine with reasonable safety.
MHRA always want to encourage people to be involved in their healthcare and are in the process of holding public consultations for conditions that are suitable for self-care. Further information on reclassification can be found here.